Gabapentin, a medication approved for treating seizures and shingles-related neuralgia, has been found to increase the risk of developing dementia and mild cognitive impairment (MCI), particularly in adults between 35-49 years old.
A new study published in Regional Anesthesia & Pain Medicine analyzed data from over 26,000 adults with chronic pain and found that those who received six or more gabapentin prescriptions for lower back pain were at a higher risk of developing dementia and MCI. The study’s findings suggest that this increased risk is more pronounced among younger adults, with the risks doubling in those aged 35-49 years.
Researchers discovered that gabapentin may have a greater cognitive impact on non-elderly individuals due to their existing age-related risk for neurodegeneration. The study highlights the importance of monitoring patients prescribed gabapentin for chronic back pain and being aware of potential cognitive decline symptoms, such as confusion or poor memory.
While the study’s results warrant further investigation into the underlying mechanisms of gabapentin’s impact on cognition, experts caution that any medication carries risks. Dr. Neel Anand, a board-certified orthopedic spine surgeon, notes that it is essential to be aware of potential side effects and to take a cohort-based approach when studying medication effects.
The study’s findings emphasize the need for physicians to closely monitor patients taking gabapentin and for individuals to report any cognitive concerns to their healthcare provider. As with any medication, caution is necessary when prescribing gabapentin, particularly in younger adults or those at risk for neurodegeneration.
Source: https://www.medicalnewstoday.com/articles/gabapentin-users-may-face-85-higher-risk-of-cognitive-impairment